uniQure N.V.
QUREuniQure N.V. is a biotechnology company focused on developing gene therapy treatments for genetic and other life-threatening diseases. Founded in the Netherlands, it specializes in delivering gene therapies using adeno-associated virus (AAV) vectors to address rare, serious conditions such as hemophilia and neurological disorders.
Company News
Law firm Kessler Topaz Meltzer & Check is investigating potential securities law violations by uniQure N.V. after the FDA rejected the company's gene therapy AMT-130 for Huntington's disease, citing insufficient evidence. The rejection caused uniQure's stock to plummet over 50% on November 3, 2025, from $67.69 to $34.29.
Law firm Kessler Topaz Meltzer & Check is investigating potential securities law violations by uniQure N.V. after the FDA rejected sufficient evidence for the company's AMT-130 gene therapy BLA submission on November 3, 2025. The announcement caused uniQure's stock to plummet over 50%, falling from $67.69 to $34.29. The firm is encouraging affect...
Law firm Kessler Topaz Meltzer & Check is investigating potential securities law violations by uniQure N.V. after the FDA rejected the company's Biologics License Application for AMT-130, a gene therapy for Huntington's disease. The rejection caused uniQure's stock to plummet over 50% on November 3, 2025, from $67.69 to $34.29. The firm is encour...
uniQure received FDA notification that its gene therapy data for AMT-130 does not sufficiently support a Biologics License Application for Huntington's disease treatment, causing significant stock price decline.
uniQure N.V. experienced a significant stock price drop after the FDA raised concerns about the data supporting its gene therapy AMT-130 for Huntington's disease, potentially delaying its Biologics License Application submission.
